NEXTBio Capital Management LP Purchases Shares of 149,750 Oculis Holding AG $OCS

NEXTBio Capital Management LP purchased a new stake in shares of Oculis Holding AG (NASDAQ:OCS) in the fourth quarter, according to its most recent filing with the Securities & Exchange Commission. The firm purchased 149,750 shares of the company’s stock, valued at approximately $2,991,000. Oculis comprises 1.8% of NEXTBio Capital Management LP’s portfolio, making the stock its 20th largest position.

A number of other institutional investors have also made changes to their positions in the stock. Marshall Wace LLP acquired a new position in shares of Oculis in the fourth quarter valued at approximately $914,000. Alyeska Investment Group L.P. grew its holdings in shares of Oculis by 152.3% in the fourth quarter. Alyeska Investment Group L.P. now owns 331,332 shares of the company’s stock valued at $6,617,000 after purchasing an additional 200,000 shares in the last quarter. HRT Financial LP acquired a new position in shares of Oculis in the fourth quarter valued at approximately $876,000. SR One Capital Management LP grew its holdings in shares of Oculis by 98.8% in the fourth quarter. SR One Capital Management LP now owns 641,022 shares of the company’s stock valued at $12,801,000 after purchasing an additional 318,522 shares in the last quarter. Finally, Renaissance Technologies LLC acquired a new position in shares of Oculis in the fourth quarter valued at approximately $499,000. 22.30% of the stock is currently owned by institutional investors and hedge funds.

Analyst Ratings Changes

OCS has been the subject of several analyst reports. Weiss Ratings reiterated a “sell (d-)” rating on shares of Oculis in a report on Tuesday, April 21st. Needham & Company LLC lowered their target price on shares of Oculis from $46.00 to $38.00 and set a “buy” rating for the company in a report on Monday, June 1st. JPMorgan Chase & Co. lowered their target price on shares of Oculis from $42.00 to $23.00 and set an “overweight” rating for the company in a report on Wednesday, June 3rd. Stifel Nicolaus lowered their target price on shares of Oculis from $50.00 to $40.00 and set a “buy” rating for the company in a report on Monday, June 1st. Finally, HC Wainwright restated a “buy” rating on shares of Oculis in a report on Thursday. Nine research analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the stock. According to data from MarketBeat, the stock currently has an average rating of “Moderate Buy” and a consensus price target of $38.33.

Oculis Trading Up 0.8%

Shares of Oculis stock opened at $11.09 on Friday. The company has a fifty day simple moving average of $24.99 and a 200-day simple moving average of $24.65. Oculis Holding AG has a 12-month low of $10.52 and a 12-month high of $34.47. The company has a current ratio of 5.18, a quick ratio of 5.18 and a debt-to-equity ratio of 0.01. The stock has a market cap of $643.00 million, a price-to-earnings ratio of -5.21 and a beta of 0.23.

Oculis (NASDAQ:OCS) last released its quarterly earnings results on Friday, May 8th. The company reported ($0.63) EPS for the quarter, missing the consensus estimate of ($0.49) by ($0.14). Oculis had a negative net margin of 8,460.67% and a negative return on equity of 56.78%. The business had revenue of $0.26 million during the quarter, compared to analysts’ expectations of $0.25 million. On average, equities analysts forecast that Oculis Holding AG will post -2.27 EPS for the current fiscal year.

Oculis Profile

Oculis SA (NASDAQ: OCS) is a clinical-stage biopharmaceutical company focused on developing novel ophthalmic therapies designed primarily to treat retinal and neuro-ophthalmic diseases. Leveraging its proprietary technology platforms, Oculis aims to deliver therapeutic agents to the back of the eye through topical or nasal administration, potentially offering an alternative to current intravitreal injections. The company’s pipeline includes OCS-01, a topical dexamethasone formulation targeting diabetic macular edema; OCS-05, a neuroprotective candidate for acute optic neuritis and idiopathic intracranial hypertension; and OC-02, a nasal spray formulation of varenicline for dry eye disease.

Founded in 2016 and headquartered in Basel, Switzerland, Oculis operates research and development facilities across Europe and in the United States, with a presence in Cambridge, Massachusetts.